ZEISS Expands Ophthalmic Portfolio in Canada with Advanced Diagnostics and Therapeutics
Event summary
- ZEISS launched enhanced diagnostic and therapeutic solutions for ophthalmic workflows in Canada on March 24, 2026.
- New offerings include CLARUS 700 with ICGA for advanced retinal imaging and VISULAS green laser for glaucoma treatment.
- VISUCORE 500 and VISUREF 600 refraction devices streamline optometry workflows.
- ZEISS FORUM subscription packages provide digital data management for clinics.
The big picture
ZEISS's expansion in Canada aligns with the broader trend of digital transformation in healthcare, where integrated workflow solutions are becoming essential for efficiency. The company's focus on precision eye care reflects the growing demand for advanced diagnostic and therapeutic technologies in ophthalmology. With a global presence and significant revenue, ZEISS is positioning itself as a key player in the medical technology sector.
What we're watching
- Market Penetration
- How ZEISS will leverage its expanded portfolio to gain market share in Canada's competitive ophthalmology sector.
- Technological Integration
- Whether clinics will fully adopt digital workflow tools like ZEISS FORUM for consistent clinical review.
- Regulatory Compliance
- The pace at which new diagnostic and therapeutic solutions will receive regulatory approvals in other markets.
Related topics